Torezolid trius May 8, 2011 · Study Will Examine Efficacy and Safety of IV and Oral Dosing of Torezolid Phosphate in Patients With ABSSSI. 17。 Dec 31, 2003 · Trius Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. Oxazolidinone resistance in clinical staphylococci is most often associated with mutations in 23S rRNA domain V, in particular G2576T ( Escherichia coli numbering) ( 24 , 30 ). May 4, 2011 · SAN DIEGO, May 4, 2011 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. Trius acquired worldwide rights to Torezolid outside of Korea, from Dong-A Pharmaceutical Co. About Trius Therapeutics. The structure-activity relationships (SAR) of oxazolidinones have been extensively reported, starting with the original ox-azolidinone SAR developed at DuPont (25, 26, 54), followed by SAR studies that led to the discovery of LZD by Pharmacia Feb 28, 2011 · Jeffrey Stein, President and Chief Executive Officer of Trius, further commented, "These data further support our objective of expanding the development of torezolid phosphate for lung infections caused by Staphylococcus and Streptococcus bacterial pathogens. [2] Tedizolid (TR-700; Trius Therapeutics, Inc. In September of 2008, Trius entered into a five-year contract with the National Institute of Allergies and Infectious Disease (NIAID), a component of the National Institutes of Health, under which Trius may receive up to $27. (Nasdaq:TSRX) today announced results from its Phase 1 clinical trial to evaluate the ability of torezolid to penetrate into Sep 14, 2009 · https://orcid. S. announced results from its Phase 1 clinical trial evaluating the safety, tolerability and pharmacokinetics of the intravenous (IV) dosage form of torezolid phosphate, an IV and orally administered second generation oxazolidinone for the treatment of serious gram positive infections, including methicillin-resistant Staphylococcus aureus (MRSA). If successfully developed, we expect torezolid phosphate to be the only once-a-day Mar 24, 2011 · Additionally, Trius plans to make Torezolid available in both an oral and IV formulation, providing an advantage to Pfizer’s Tygacil and Cubist’s Cubicin. Molecular weights are 370. May 18, 2009 · Best Places to Work; Employer Resources; Post Jobs; Talent Solutions; Advertise; Submit a Press Release Aug 19, 2010 · /PRNewswire-FirstCall/ -- Trius Therapeutics, Inc. (Nasdaq:TSRX) today announced results from its Phase 1 clinical trial to evaluate the ability of torezolid to penetrate into May 19, 2010 · This is the second government-funded research contract that has been awarded to Trius. Jun 16, 2010 · SAN DIEGO, June 16 /PRNewswire/ -- Trius Therapeutics, Inc. (Nasdaq: TSRX ) today reported new findings on torezolid phosphate (TR-701), a second generation oxazolidinone antibiotic now in Phase 3 clinical development. (Nasdaq:TSRX) today announced results from its Phase 1 clinical trial to evaluate the ability of torezolid to penetrate into Jul 27, 2011 · Trius to Host a Conference Call Today at 7:00 a. 24% and Bayer Pharma AG today announced that they have signed an exclusive agreement to develop and commercialize Trius’ lead Phase 3 antibiotic, torezolid phosphate (torezolid), in China, Japan and all other countries in Asia, Africa, Latin America and the Middle East, excluding Trius Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. Linezolid (LZD) resistance was first associated with mutations in the domain V region of 23S rRNA genes (G2576T) ( 7 , 30 ). [18] Abstract. Patients will receive the IV torezolid for >=1 day and then oral torezolid at the investigator's discretion. (lot DP-70-1465 May 19, 2010 · SAN DIEGO, May 19 /PRNewswire/ -- Trius Therapeutics, Inc. On a pro forma basis, accounting for the net cash proceeds of its Initial Public Offering (IPO) which Jan 10, 2011 · "Trius provides a unique opportunity to launch torezolid phosphate, a best-in-class oxazolidinone, and to contribute to the development of its preclinical portfolio," stated Craig Thompson. About Europe PMC; Preprints in Europe PMC Jul 27, 2011 · Torezolid, the company's most-advanced product candidate, is undergoing a phase III trial in oral dosage form for the treatment of ABSSSI (acute bacterial skin and skin structure infections). These three products generated sales SAN DIEGO, Feb. Tedizolid phosphate (formerly torezolid; Cubist Pharmaceuticals) is the first of the next generation of oxazolidinones to obtain Food and Drug Administration (FDA) approval. , bacterial killing) activity, lower frequency of resistance, activity against linezolid-resistant bacterial strains and an improved safety profile. A number of similarities exist between tedizolid and its predecessor linezolid. ) Trius said that Torezolid phosphate (TR-701) is currently in Phase 3 clinical testing in patients with acute bacterial skin and skin structure infections (ABSSSI). Aug 7, 2013 · Tedizolid phosphate (previously known as torezolid phosphate) is a novel oxazolidinone prodrug antibiotic. 2，保护期至2024. May 25, 2011 · Trius intends to use the net proceeds of the transaction to fund the continued clinical development of torezolid phosphate, and for general corporate purposes. (Nasdaq:TSRX), announced today that the results of two studies of torezolid phosphate (TR-701) will be presented at the upcoming Increasing incidences of clinical resistance to LZD and the potential for rapid horizontal dissemination of cfr have contributed to the demand for expanded-spectrum oxazolidinones such as TR-700 (torezolid), the active antibacterial moiety of the prodrug TR-701 (torezolid phosphate) (Fig. Patent and Trademark Office Mar 29, 2010 · Trius believes that these results, coupled with data from the prior Phase 1 and Phase 2 clinical trials of the oral dosage form of torezolid phosphate, provide the clinical basis for Trius to Jul 27, 2011 · Trius Therapeutics and Bayer Form Strategic Collaboration to Develop and Commercialize Torezolid Phosphate in Asia-Pacific and Emerging Markets Trius to Host a Conference Call Today at 7:00 a. It is significantly differentiated from Zyvox(R) (linezolid), the only marketed drug in this class. Conclusion Torezolid phosphate (TR-701) is the phosphate monoester prodrug of the oxazolidinone TR-700 which demonstrates potent in vitro activity against Gram-positive bacteria, including methicillin-susceptible Staphylococcus aureus (MSSA) and methicillin-resistant Apr 11, 2011 · SAN DIEGO, April 11, 2011 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. Oct 26, 2010 · Patents which may issue from these additional applications could provide patent exclusivity for torezolid phosphate through 2030. 7,816,379 which covers the composition of matter of torezolid phosphate (TR-701), the Company's lead investigational drug, has been extended by one thousand one hundred sixty-three Four oxazolidinones are currently undergoing clinical evaluation. 25 /PRNewswire/ -- Trius Therapeutics, Inc. Such statements include, but are not limited to, statements regarding the potential efficacy of torezolid phosphate in treating lung infections, including as compared to linezolid and quinolone antibiotics, the ability of Trius to expand the development and use of torezolid phosphate to lung infections, and whether torezolid phosphate, if Jun 8, 2009 · About Torezolid (TR-701) Torezolid is a second-generation IV/oral antibacterial drug in the oxazolidinone class. (Torezolid phosphate-free acid is the formulation to be used in future clinical trials. Piper Jaffray & Co. , in January 2007. 28, 2011 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. Patent and Trademark Office The specific potential advantages that Trius believes torezolid phosphate (TR-701) offers include: greater potency, once daily dosing, a shorter course of therapy, in vivo bactericidal (i. For each experiment, TR-701 (lot 287/07-TR3) was dissolved in sterile water. (Nasdaq:TSRX) and Bayer Pharma AG today announced that they have signed an exclusive agreement to develop and commercialize Trius' lead Phase 3 antibiotic, torezolid phosphate (torezolid), in China, Japan and all other countries in Asia, Africa, Latin America and the Middle East, excluding North and South Korea. Locke, Mark Hilgers, and Karen Joy Shaw* Trius Therapeutics, Inc. Pacific Time (10:00 a. Linezolid (lot 1000891018) was obtained from Pfizer, Inc. Comparative In Vitro Antimicrobial Activities of Torezolid (TR-700), the Active Moiety of a New Oxazolidinone, Torezolid Phosphate was provided by Trius Pharmaceuticals, Inc. 28 for torezolid phosphate disodium salt. 34 for torezolid, 450. served as sole lead placement agent and Ladenburg Thalmann & Co. , 6310 Nancy Ridge Road, Suite 105, San Diego, California 92121, 1 SERRG, Inc. announced results from its Phase 2 clinical trial evaluating the safety and efficacy of oral torezolid (TR-701) for the treatment of severe complicated skin and skin Jul 27, 2011 · SAN DIEGO, July 27, 2011 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. In addition to the company's torezolid phosphate clinical program, it is currently conducting three preclinical programs using its proprietary discovery platform to develop antibiotics to treat infections caused Jul 27, 2011 · Trius to Host a Conference Call Today at 7:00 a. Jul 27, 2011 · SAN DIEGO, July 27, 2011 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. The in vitro activity of tedizolid (previously known as torezolid, TR-700) against penicillin-resistant Streptococcus pneumoniae (PRSP) clinical isolates and the in vivo efficacy of tedizolid phosphate (torezolid phosphate, TR-701) in murine models of PRSP systemic infection and penicillin-susceptible S. aure … Apr 11, 2011 · SAN DIEGO, April 11, 2011 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. Trius Therapeutics and Bayer Form Strategic Collaboration to Develop and Commercialize Torezolid Phosphate in Asia Oct 25, 2010 · Provides patent exclusivity through late 2026SAN DIEGO, Oct. Trius Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious, life-threatening infections. 1–4 Tedizolid inhibits the synthesis of bacterial proteins by interacting with the 50S subunit of bacterial ribosome, resulting in inhibition of protein synthesis. The biotech reports that Bayer is handing over a $25 million Feb 28, 2011 · Jeffrey Stein, President and Chief Executive Officer of Trius, further commented, "These data further support our objective of expanding the development of torezolid phosphate for lung infections caused by Staphylococcus and Streptococcus bacterial pathogens. (Nasdaq:TSRX) announced today that it has reached agreement with the United States Food and Drug Administration (FDA), under the Special Protocol Assessment (SPA) process, on the design of its second planned Phase 3 study for the intravenous and oral dosage forms of torezolid phosphate for treatment of acute bacterial skin Dec 1, 2009 · The oxazolidinone torezolid maintained a ≥8-fold potency advantage over linezolid for both strains. pneumoniae (PSSP) pneumonia were examined using linezolid as a comparator. ). (Nasdaq: TSRX) announced today the issuance of Patent Number 7,816,379, entitled Aug 5, 2011 · SAN DIEGO, Aug. , San Diego, CA). today announced that it has been awarded a new four and a half year contract from the Defense Threat Reduction Agency (DTRA), an agency Jun 8, 2009 · Trius Therapeutics, Inc. The structure-activity relationships (SAR) of oxazolidinones Risks that contribute to the uncertain nature of the forward-looking statements include: Trius’ ability to obtain additional financing; Trius’ use of the net proceeds from the IPO; the accuracy of the company’s estimates regarding expenses, future revenues and capital requirements; the success and timing of Trius’ preclinical studies Trius holds an exclusive license to torezolid phosphate for territories outside of North and South Korea from Dong-A Pharmaceuticals. There has been an ongoing effort to develop second-generation oxazolidinones , and currently there are two in clinical development: TR-701 (torezolid phosphate; Trius Therapeutics, Inc. Here we investigated the potential of Staphylococcus aureus strains TR-700 (torezolid), the active moiety of the novel oxazolidinone phosphate prodrug TR-701, is highly potent against gram-positive pathogens, including strains resistant to linezolid (LZD). August 2011 06:00 ET | Quelle: Trius Therapeutics, Inc. (Nasdaq:TSRX) and Bayer Pharma AG today announced that they have signed an exclusive Trius Therapeutics, Inc. Apr 11, 2011 · SAN DIEGO, April 11, 2011 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. 5, 2011 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. In addition to the company’s torezolid phosphate clinical program, it is currently conducting three preclinical programs using its proprietary discovery platform to develop antibiotics to treat infections Sep 13, 2010 · /PRNewswire-FirstCall/ -- Trius Therapeutics, Inc. Joseph Surber, Chief Medical Officer Torezolid (TR-700) is the active moiety of the prodrug torezolid phosphate ([TP] TR-701), a second-generation oxazolidinone with 4- to 16-fold greater potency than linezolid against Gram-positive species including methicillin-resistant Staphylococcus aureus (MRSA). (Nasdaq: TSRX), a biopharmaceutical company focused on the discovery, development and commercialization of Sep 16, 2009 · Torezolid was obtained as microbiological standard from Trius Therapeutics (San Diego, CA, USA). announced today that it has reached agreement with the United States Food and Drug Administration (FDA), under the Special Protocol Assessment (SPA) process, on the design of its planned Phase 3 study for the oral dosage form of torezolid phosphate for treatment of acute bacterial skin and skin structure infections (ABSSSI). m. pyogenes, S Trius was founded by the last Chief Financial Officer John Schmid and Chief Scientific Officer John Finn. The Torezolid (TR-700) standardized powder was provided by Trius Pharmaceuticals, Inc. served as Apr 11, 2011 · SAN DIEGO, April 11, 2011 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. The other antibiotics were obtained as the clinical products for intravenous administration to humans and complying with the European Pharmacopoeia [gentamicin as GEOMYCINE® (distributed in Belgium by GlaxoSmithKline, Genval); and linezolid as Jul 27, 2011 · SAN DIEGO, July 27, 2011 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. Tedizolid is being developed for treatment of serious infections caused by Gram-positive organisms, including MRSA. Apr 15, 2014 · Tedizolid is an investigational oxazolidinone antibiotic for the treatment of multidrug-resistant gram-positive pathogens such as MRSA, Streptococcus pneumoniae, and VRE, including some linezolid-resistant strains. Trius has licensed patents in Australia, New Zealand and India, and a patent application in Russia where a notice of allowance was recently issued. e. Europe PMC. Subjects were administered a single oral dose of 600 mg tedizolid phosphate (the prodrug) and a hand and mouth check was performed for verification. Two solid forms of the prodrug have been used in clinical and nonclinical testing: tedizolid phosphate disodium (TPD, TR-701) used in early development studies and the free acid tedizolid phosphate (TR-701 FA) selected for its relative Tedizolid phosphate is rapidly converted in vivo to tedizolid (previously referred to as torezolid). Trius Therapeutics and Bayer Form Strategic Collaboration to Develop and Commercialize Torezolid Phosphate in Asia Jan 5, 2014 · Torezolid (also known as TR-701 and now tedizolid[1]) is an oxazolidinone drug being developed by Trius Therapeutics (originator Dong-A Pharmaceuticals) for complicated skin and skin-structure infections (cSSSI), including those caused by Methicillin-resistantStaphylococcus aureus (MRSA). 30 Trius Therapeutics, Inc. Aug 30, 2010 · Risks that contribute to the uncertain nature of the forward-looking statements include: Trius’ ability to obtain additional financing; Trius’ use of the net proceeds from the IPO; the accuracy of the company’s estimates regarding expenses, future revenues and capital requirements; the success and timing of Trius’ preclinical studies Study drug was supplied in 200 mg capsules (Trius Therapeutics, Inc. Patent and Trademark Office Jul 27, 2011 · Eyeing the pharma prize in emerging markets, Bayer Pharma is partnering up with San Diego-based Trius Therapeutics on its lead antibiotic. , 6310 Nancy Ridge Drive, Suite 105, San Diego, California 92121 Received 26 June 2009/Returned for modification 31 July 2009/Accepted 3 September 2009 医药魔方NextPharma®全球新药数据库为您提供「特地唑胺」药品的基本信息（药品名称、药品类别、靶点、作用机制、药品简介、研发机构、最高研发阶段、审评审批类型、外置链接）。 Mar 30, 2010 · The study also demonstrated high oral bioavailability of torezolid phosphate. Jul 27, 2011 · SAN DIEGO, Jul 27, 2011 (GlobeNewswire via COMTEX) -- Trius Therapeutics, Inc. (NASDAQ:TSRX) granted Bayer AG (Xetra:BAY) exclusive rights to antibiotic candidate torezolid in China, Japan, Africa, Latin America, the Middle East, and all other countries in Asia, excluding North and South Korea. Patent No. (Nasdaq: TSRX) announced that the first patient has been dosed in its Phase 3 clinical study of the oral dosage form of torezolid phosphate for the Feb 28, 2011 · SAN DIEGO, Feb. [2] Trius holds an exclusive license to torezolid phosphate for territories outside of North and South Korea from Dong-A Pharmaceuticals. Patent and Trademark Office Jan 25, 2011 · Phase 2 Data Impresses In 2009, Trius initiated double-blind Phase 2 study that evaluated three oral doses of Torezolid (200, 300, or 400mg) QD over 5-7 days for complicated skin and skin To investigate the structural basis for oxazolidinone activity against LZD-resistant (LZD(r)) strains, we compared structurally diverse, clinically relevant oxazolidinones, including LZD, radezolid (RX-1741), TR-700 (torezolid), and a set of TR-700 analogs (including novel CD-rings and various A-ring C-5 substituents), against a panel of Sep 7, 2010 · In addition to the results of clinical and nonclinical studies of torezolid phosphate, the posters highlight advances in Trius' preclinical GyrB and DHFR antibacterial and antifungal programs. (lot DP-70-1465/wt). 1) (). Advantages of torezolid over linezolid include: About Trius Therapeutics Aug 30, 2010 · Trius Therapeutics Initiates Phase 3 Program of Oral Torezolid Phosphate for the Treatment of ABSSSI First ABSSSI Study Being Conducted Under an SPA with New Early Nov 9, 2024 · Trius Therapeutics, Inc. Trius Therapeutics, Inc. 1 Tedizolid has been shown to have activity against clinically relevant gram Mar 12, 2019 · 磷酸特地唑胺最早由韩国Dong-A 制药开发，一款二代恶唑烷酮类抗生素，辗转后授权Trius Therapeutics，Cubist （Merck & Co）和 Bayer进行商业化开发，在2014年06月20日获得美国FDA批准上市，2015年6月在欧盟上市。在中国化合物专利ZL200480037612. [16] Other executives included Chief Executive Officer Jeffrey Stein, Chief Medical Officer Philippe Prokocimer, Chief Commercial Officer Craig Thompson, [17] and Chief Development Officer Ken Bartizal. Patent and Trademark Office (torezolid phosphate; Trius Therapeutics, Inc. 4 million. , 5210 Armour Road Suite 400, Columbus, Georgia 31904, 2 eStudy Site, 752 Medical Center Court, Suite 105, Chula Vista, California 91911, 3 Ordway Research Institute, 150 New Scotland Avenue, Albany, New York 12208, 4 Duke Clinical Research Institute, 2400 Pratt Street, Durham, North Carolina Apr 11, 2011 · SAN DIEGO, April 11, 2011 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that the Company has received official notification from the U. Get more Bioprocess insight with our FREE newsletter sign me up Jun 8, 2009 · "I was impressed by the rapid clinical effect of oral torezolid in curing severe skin infections caused by MRSA and other gram-positive pathogens," said Dr. (Nasdaq:TSRX) today announced results from its Phase 1 clinical trial to evaluate the ability of torezolid to penetrate into AdditionaL FederaL Contracts BoLster EarLy Stage PipeLine In addition to advancing our torezolid clinical program we are continuing to progress on our preclinical and Aug 5, 2011 · Study Will Examine Efficacy and Safety of IV and Oral Dosing of Torezolid Phosphate in Patients With ABSSSI. ) and radezolid (RX-1741; Rib-X Pharmaceuticals, Inc. TR-700 (torezolid), the active moiety of the novel oxazolidinone phosphate prodrug TR-701, is highly potent against gram-positive pathogens, including strains resistant to linezolid (LZD). Aug 15, 2011 · Trius received an SPA from FDA for a double-blind Phase III trial evaluating once-daily 200 mg IV and oral torezolid for 6 days vs. 32 for torezolid phosphate-free acid, and 494. Cefotaxime (lot 036K1623), oxacillin (lot 085K1923), levofloxacin (lot 1333515), and penicillin (lot 095K0625) were purchased from Sigma. The Trius Therapeutics compound tedizolid phosphate (formerly known as torezolid phosphate, TR-701, DA-7218), the most advanced, is in phase 3 clinical trials for acute bacterial skin and skin structure infections. Linezolid and Torezolid (TR-700) Jeffrey B. Jan 4, 2014 · Torezolid (also known as TR-701 and now tedizolid[1]) is an oxazolidinone drug being developed by Trius Therapeutics (originator Dong-A Pharmaceuticals) for complicated skin and skin-structure infections (cSSSI), including those caused by Methicillin-resistantStaphylococcus aureus (MRSA). If successfully developed, we expect torezolid phosphate to be the only once-a-day Aug 5, 2011 · SAN DIEGO, Aug. The structure of the phosphate monoester prodrug, TR-701, and its active molecule, TR-700, are shown in Fig. /quotes/zigman/117176 TSRX +4. Sep 14, 2009 · TR-700 (torezolid), the active moiety of the novel oxazolidinone phosphate prodrug TR-701, is highly potent against gram-positive pathogens, including strains resistant to linezolid (LZD). TR-700 (lot 1040-69-2) was dissolved in dimethyl sulfoxide Feb 1, 2011 · Torezolid (TR-700) is the active moiety of the prodrug torezolid phosphate ([TP] TR-701), a second-generation oxazolidinone with 4- to 16-fold greater potency than linezolid against Gram-positive May 1, 2010 · The present study was designed to (i) assess the in vitro antibacterial activity of torezolid and compare its activity with that of linezolid, cefotaxime, and levofloxacin against a broad range of bacterial pathogens for which torezolid might be considered for therapy; (ii) determine the appropriate disk mass for disk diffusion antimicrobial susceptibility testing; (iii) determine preliminary Jan 26, 2025 · The Company is developing torezolid phosphate, an intraveneous (IV) and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections (ABSSSI), and subsequently for other indications. Menu. announced that on February 26th, 2010, the FDA issued new draft guidance on non-inferiority clinical trials that will apply to the design Feb 28, 2011 · SAN DIEGO, Feb. May 8, 2011 · SAN DIEGO, Aug. (Nasdaq:TSRX) announced today that it has reached agreement with the United States Food and Drug Administration (FDA), under the Special Protocol Assessment (SPA) process, on the design of its second planned Phase 3 study for the intravenous and oral dosage forms of torezolid phosphate for treatment of acute bacterial skin SAN DIEGO, Aug. Feb 28, 2011 · SAN DIEGO, Feb. Mar 1, 2010 · Scattergrams of torezolid versus zone diameters (20-g disks). Sep 13, 2010 · Trius Therapeutics, Inc. Tedizolid is currently approved by the FDA for the treatment of ABSSSIs at a dose of 200 mg orally or intravenously once daily for a total of 6 days [ 21 ]. org. Trius Therapeutics and Bayer Form Strategic Collaboration to Develop and Commercialize Torezolid Phosphate in Asia Dec 1, 2010 · (torezolid phosphate; Trius Therapeutics, Inc. Jul 28, 2011 · Trius Therapeutics Inc. Over time, a variety of 23S rRNA mutations have been identified, and these remain the most commonly reported class of mutation leading to LZD resistance ( 5 Sep 13, 2010 · There has been an ongoing effort to develop second-generation oxazolidinones , and currently there are two in clinical development: TR-701 (torezolid phosphate; Trius Therapeutics, Inc. 05. (A) All staphylococci combined using transmitted light (n 338). A double-blind phase 2 study evalu … Trius acquired worldwide rights outside of North and South Korea to a family of patent applications that provide patent coverage for composition of matter and methods of making and using torezolid Jul 28, 2011 · Trius Therapeutics Inc. Tedizolid was approved by the U. S Food and Drug Administration (FDA) on June 20, 2014, with the indication for the treatment of acute bacterial Skin and skin structure infections (ABSSSI) caused by certain susceptible bacteria, including Staphylococcus aureus (including methicillin-resistant strains, MRSA, and methicillin-susceptible strains), various Streptococcus species (S. (Nasdaq: TSRX) today reported new findings on torezolid phosphate (TR-701), a second generation Oct 25, 2010 · SAN DIEGO, Oct. Trius Therapeutics and Bayer Form Strategic Collaboration to Develop and Commercialize Torezolid Phosphate in Asia 370. (Nasdaq: TSRX) announced today the issuance of Patent Number 7,816,379, entitled "Oxazolidinone Derivatives," by the United States Oct 26, 2010 · Best Places to Work; Employer Resources; Post Jobs; Talent Solutions; Advertise; Submit a Press Release Sep 13, 2010 · All isolates had TR-700 (torezolid) MIC values of ≤2 μg/ml. Inc. Here we investigated the potential of Staphylococcus aureus Jul 27, 2011 · Trius to Host a Conference Call Today at 7:00 a. Here we investigated the potential of Staphylococcus aureus strains ATCC 29213 (methicillin-susceptible S. Patent and Trademark Office that U. , Ltd. Trius believes that these results, coupled with data from the prior Phase 1 and Phase 2 clinical trials of the oral dosage form of torezolid phosphate, provide the clinical basis for Trius to proceed with its Phase 3 clinical trials planned for the second half of 2010. (B) All staphylococci combined using reflected light (n 338). 17) were supplied by Trius Therapeutics (San Diego, CA). 7 million. twice-daily 600 mg Zyvox linezolid for 10 days in 658 patients. Mar 15, 2010 · Torezolid (TR-700) standardized powder was provided by Trius Pharmaceuticals, Inc. The structure-activity relationships (SAR) of oxazolidinones have been extensively reported, starting with the original ox-azolidinone SAR developed at DuPont (25, 26, 54), followed by SAR studies that led to the discovery of LZD by Pharmacia However since then, it has been developed, studied, and marketed by a number of pharmaceutical companies including Trius Therapeutics, Cubist, and most recently Merck . , San Diego, CA) is the active moiety of the prodrug tedizolid phosphate (TR-701), a novel once-daily oral or intravenous agent with attributes that distinguish it from other oxazolidinones. Patent and Trademark Office Nov 29, 2010 · The study drug was supplied as 200 mg of torezolid phosphate disodium salt capsules and could be taken with or without food. , 6310 Nancy Ridge Drive, Suite 105, San Diego, California 92121 TR-700 (torezolid), the active moiety of the novel oxazolidinone phosphate prodrug TR-701, is highly potent. Jun 16, 2010 · This press release contains forward-looking statements regarding Trius' planned activities under the Phase 3 clinical trial for the oral dosage form of torezolid phosphate. Aug 5, 2011 · This press release contains forward-looking statements regarding Trius' planned activities under the second Phase 3 clinical trial for the IV and oral dosage form of torezolid phosphate. We have successfully completed two Phase 3 clinical trials for Tedizolid Phosphate (TR-701), formerly torezolid phosphate, in ABSSSI. aureus ATCC 25923 in broth (left panels) or after phagocytosis by THP-1 macrophages (middle panels) or HUVECs (torezolid phosphate; Trius Therapeutics, Inc. August 05, 2011 06:00 ET | Source: Trius Therapeutics, Inc. About DTRA & TMTI Apr 12, 2011 · SAN DIEGO, April 11, 2011 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. About. served as co-placement agent for the transaction, and Citigroup Global Markets Inc. 12. Aug 19, 2010 · Trius ended the second quarter of 2010 with cash and cash equivalents totaling $10. "The package of data Trius is presenting at ICAAC provides compelling evidence of the high efficacy of torezolid against difficult to treat bacterial skin infections, including potency against Sep 1, 2009 · Concentration-dependent effects of linezolid (LZD) and torezolid (TR-700) towards S. Jul 27, 2011 · Trius to Host a Conference Call Today at 7:00 a. 7,816,379 which covers the composition of matter of torezolid phosphate (TR-701), the Company’s lead investigational drug, has been extended by one thousand one hundred sixty Jul 27, 2011 · SAN DIEGO, July 27, 2011 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. announced that on February 26th, 2010, the FDA issued new draft guidance on non-inferiority clinical trials that will apply to the design of the Company's Mar 1, 2010 · SAN DIEGO, March 1 /PRNewswire/ --Trius Therapeutics, Inc. 1.
oifs yzs pxv bggwgm npher qmb kru nauwzffh jmoo upmwnw gdziy kaz oxj rctry ksekrh